Asia-Pacific Peptide Regulations
Overview of peptide regulations across major Asia-Pacific markets.
Introduction
Asia-Pacific regulations range from very strict to moderate on paper. None of these countries treats peptides as a separate legal category: a peptide sold for health use is regulated as a medicine. Australia and New Zealand have their own page, and other regions are on the regional regulations hub.
Major Market Regulations
The tables follow each regulator's published rules as of October 2026.
Japan
| Factor | Status |
|---|---|
| Regulatory body | MHLW, with PMDA |
| Import | Prescription drugs: 1 month's supply without paperwork |
| Injectables | Only pre-filled syringes or self-injection kits |
South Korea
| Factor | Status |
|---|---|
| Regulatory body | MFDS |
| Import | 6 bottles or 3 months' supply, with prescription |
| Access | Controlled drugs need an MFDS permit |
China
| Factor | Status |
|---|---|
| Regulatory body | NMPA |
| Domestic manufacturing | Major hub |
| Domestic use | Sale needs NMPA approval |
In March 2026, US Customs reported seizing about 5,000 mislabeled peptide parcels from a shipper in China.
Thailand
| Factor | Status |
|---|---|
| Regulatory body | Thai FDA |
| Personal import | 30 days' supply with prescription; no mail orders |
| Clinic availability | Advertised in Bangkok (unverified) |
Singapore
| Factor | Status |
|---|---|
| Regulatory body | HSA |
| Control level | Strict |
| Import | Up to 3 months' supply, prescribed to the traveller |
India
| Factor | Status |
|---|---|
| Regulatory body | CDSCO |
| Manufacturing | Significant; 12 generic semaglutide makers since March 2026 |
| Personal import | 100 average doses per drug in baggage |
Comparative Overview
Strictness Ranking
Our reading of the written rules, not an official scale.
| Country | Strictness | Notes |
|---|---|---|
| Japan | Very strict | Injectables only pre-filled |
| Singapore | Very strict | Nothing over 3 months |
| South Korea | Strict | Medical pathway exists |
| China | Strict | Approval for domestic sale |
| Thailand | Strict on paper | Looser clinic practice |
| India | Moderate | 100-dose allowance |
Access Options
Research-use-only vials aren't approved or prescribed medicines, so in our reading none of these allowances covers them.
Travel Considerations
Transiting Through
HSA says travellers staying in Singapore's transit zone need no approval, though prohibited medications are barred even there.
What to watch next
- China: no generic semaglutide approved as of October 2026, though the patent expired March 20, 2026 (BioPharma APAC).
- India: CDSCO's follow-up after it inspected 49 entities over GLP-1 promotion in March 2026.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- Information for those who are bringing medicines for personal use into Japan (Ministry of Health, Labour and Welfare, accessed October 2026)
- Information on controlled substances and bringing prescription drugs into Korea (U.S. Embassy & Consulate in the Republic of Korea, 2026)
- Drug Administration Law of the People's Republic of China, 2019 (National People's Congress, English text)
- Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S. (U.S. Customs and Border Protection, 2026)
- Frequently asked questions: bringing drugs into Thailand for personal use (Thai FDA, accessed October 2026)
- Travelling with medications to Singapore (Health Sciences Authority, updated June 2026)
- Import of small quantities of drugs for personal use under Rule 36 (CDSCO, accessed October 2026)
- Semaglutide generics, six months in: every launch in India and where China stands (BioPharma APAC, October 2026)